The study used surveillance data from 30 European countries (EU and EEA) by 2015, and researchers investigated 16 different antibiotic and bacterial combinations. These include bacteria that are considered the common causes of hospital infection and are immediately resistant to antibiotic groups that are considered critical to human medicine.
"The biggest burden of illness is being calculated for the countries of southern Europe, and Norway and the other Nordic countries are the best, researchers are winning the Petter Elstrøm at the Norwegian Institute of Public Health who participated in the study.
Disease-inhibiting disease has increased its levels of significance over the last eight years, and the most significant is one of the infections caused by resistant Klebsiella pneumoniae and Escherichia coli. 75 percent of the burden of illness can be associated with hospitalized infections and 39 percent of obese grams of negative bacteria that are resistant to antibiotics of the last lines such as carbapenem and colistin. This leads to the fact that there are little or no effective antibiotics that can be used against infections caused by these bacteria.
In total, it was estimated that nearly 1, 900 people in the fourth quarter of the year received infection of the bacteria involved in the study. This causes about 69 additional deaths due to antibiotic-resistant bacteria. Elstrøm points out that the budgets in the study are good with the good control data we have in Norway.
– One resistant bacterium we have good tracking data in Norway is Staphylococcus aureus (MRSA) resistant to methicillin. The study estimates that 17 people in the fourth quarter receive MRSA blood infections. In the Norwegian Contagious Disease Control System (MSIS), for the year 2015, 11 people with such MRSA infections were registered. Since the cause of the infection is not always identified, I would like to say that the results in the study correspond to the data we have in Norway, both for MRSA infections and for other bacterial infections reported to MSIS, says Elstrøm.
For the first time, the burden of antibiotic-resistant bacteria is also measured in the form of DALY (Adaptive Adaptability Lifecycle). DALY is the ultimate goal of cough disease that has been lost for many years due to health, functional abilities and premature death. DALY is often used to compare loads of different illnesses or to compare cargo between countries and different population groups. DALY can and can estimate the cost of the disease. Such cost analysis is performed in a standardized way to compare costs associated with different countries.
– The study calculates that the burden of resistant bacterial diseases is about 1,700 DALYs in Norway. Turned into the crown and the ear, the burden of diseases of their resistant bacteria causes the company's annual cost of about 2 billion crowns of Norway, "says Elstrøm.
The Organization for Economic Co-operation and Development (OECD) has used the results of this study to more accurately calculate the economic burden associated with resistant bacteria. This is published in a separate report by the OECD, Stemming the Superbug Tide, which is public on November 7 this year.
Even if the burden of disease is significant and increased in Europe, it is still possible to create softness to reverse the development.
– The most important options we can do in Norway and globally are reducing antibiotic consumption. In addition, we must ensure that good contamination measures prevent the spread of resistant bacteria and contribute to the research and development of new types of antibiotics, Elstrøm says.
Approximate deaths and life-years adapted to disability caused by antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: The Lancet Modeling Analysis
Health Services Related Infections, Use of Antibiotics (NOIS), Antibiotic Resistance (MSIS) and the World Hand Hygiene. Annual Report 2017 (Norwegian Public Health Institute)
European Day of Antibiotic Consciousness (ECDC)